wiwat thavornwattanayong


OBJECTIVES: Schizophrenia is the third leading cause of loss of life years in Thailand. Currently, aripiprazole is the latest drug for the treatment of acute schizophrenia in Thailand but its cost-effectiveness has not been studied. The purpose of this study was to investigate the cost-effectiveness of aripiprazole compared with risperidone. METHODS: A Markov model was used to evaluate total costs and quality-adjusted life years (QALYs) over a life-time horizon from a societal perspective. Clinical effectiveness was retrieved from previous studies. All cost data and mortality rates were retrieved from Thai data. RESULTS: The results demonstrated that the total cost of the treatment with aripiprazole was 706,458.87 Baht compared to 694,039.57 Baht for risperidone, and the QALYs were 15.75 and 15.45 years respectively. The incremental cost-effectiveness ratio (ICER) of aripiprazole compared to risperidone was 41,466.98 Baht per QALY gained. The acceptability curves demonstrated that the probability of aripiprazole being cost-effective was 86.3% of the willingness-to-pay, being 1.2 times the Thai gross national income (GNI) per capita.  CONCLUSIONS: Although treatment of acute schizophrenia in Thailand with aripiprazole was slightly more effective, its total costs was higher and it showed 86.3% probability of cost-effectiveness. The results of this study could contribute to appropriate decision making by policy maker.

Full Text:



Chong HY, Teoh SL, Wu DB-C, Kotirum S, Chiou C-F, Chaiyakunapruk N. Global economic burden of schizophrenia: a systematic review. Neuropsychiatr Dis Treat. 2016;12:357-73.

Phanthunane P, Vos T, Whiteford H, Bertram M, Udomratn P. Schizophrenia in Thailand: prevalence and burden of disease. Popul Health Metr. 2010;8:24.

Phanthunane P, Whiteford H, Vos T, Bertram M. Economic burden of schizophrenia: empirical analyses from a survey in Thailand. J Ment Health Policy Econ. 2012;15(1):25-32.

The Royal College of Psychiatrists of Thailand. Recommendations for the Pharmacotherapy of Mental Disorders (2013). J Psychiatr Assoc Thailand. 2013;58(3):221-32.

Lin L, Zhao YJ, Zhou HJ, Khoo AL, Teng M, Soh LB, et al. Comparative cost-effectiveness of 11 oral antipsychotics for relapse prevention in schizophrenia within Singapore using effectiveness estimates from a network meta-analysis. Int Clin Psychopharmacol. 2016;31:84-92.

Gautam S, Meena PS. Drug-emergent metabolic syndrome in patients with schizophrenia receiving atypical (second-generation) antipsychotics. Indian J Psychiatry. 2011;53(2):128-33.

World Health Organization. The Selection and Use of Essential Medicines: Report of the WHO Expert Committee, 2013. Italy; 2013.

Potkin SG, Saha AR, Kujawa MJ, Carson WH, Ali M, Stock E, et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry. 2003;60:681-90.

Farah A. Atypicality of atypical antipsychotics. Prim Care Companion J Clin Psychiatry. 2005;7(6):268-74.

Kerwin R, Millet B, Herman E, Banki CM, Lublin H, Pans M, et al. A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients Schizophrenia Trial of Aripiprazole: (STAR) study. Eur Psychiat. 2007;22:433-43.

Drug And Medical Supply Information Center. Reference of Drug Costs (Updated 24 May 2017). In: Ministry of Public Health Thailand, editor. 2017.

Subcommittee of Development of National Drug List Thailand. Handbook of Health Technology Asessment for Thailand. 2 ed. Nonthaburi: Watcharin P.P. printing; 2013.

Robinson DG, Gallego JA, John M, Petrides G, Hassoun Y, Zhang J-P, et al. A Randomized Comparison of Aripiprazole and Risperidone for the Acute Treatment of First-Episode Schizophrenia and Related Disorders: 3-Month Outcomes. Schizophr Bull. 2015;41(6):1227-36.

Truven Health Analytics Micromedex solutions. Risperidone 2017 [Available from:

Truven Health Analytics Micromedex solutions. Aripiprazole 2017 [Available from:

National Institute for Health and Care Excellence. Psychosis and schizophrenia in adults: prevention and management Clinical guideline. 2014.

Davies A, Vardeva K, Loze J-Y, L’Italien GJ, Sennfalt K, Baardewijk Mv. Cost-effectiveness of atypical antipsychotics for the management of schizophrenia in the UK. Curr Med Res Opin. 2008;24(11):3275-85.

Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making. 1993;13:322-38.

National Statistical Office Ministry of Information and Communication Technology. Statistical Yearbook Thailand 2016. 2016. p. 14-31.

Hatta K, Sato K, Hamakawa H, Takebayashi H, Kimura N, Ochi S, et al. Effectiveness of second-generation antipsychotics with acute-phase schizophrenia. Schizophr Res. 2009;113:49-55.

World Health Organization. World health statistics 2016: monitoring health for the SDGs, sustainable development goals. France2016.

Srithanya Hospital Thailand. Report of the reference cost. 2017.

Standard Cost Lists for Health Technology Assessment [Internet]. 2009 [cited 24 December 2016]. Available from:

Phanthunane P, Vos T, Whiteford H, Bertram M. Health outcomes of schizophrenia in Thailand: Health care provider and patient perspectives. Asian J Psychiatr. 2010;3(4):200-5.

Sassi F. Calculating QALYs, comparing QALY and DALY calculations. Health Policy Plan. 2006;21(5):402-8.

Williams L, Robinson S, Dickinson H. Rationing in Health Care: The Theory and Practice of Priority Setting. Bristol: The Policy Press; 2012.

Subcommittee of Development of National Drug List Thailand. Handbook of Health Technology Asessment for Thailand. Nonthaburi: The Graphico Systems Co.,Ltd.; 2009.

Chan H-Y, Lin W-W, Lin S-K, Hwang T-J, Su T-PT, Chiang S-C, et al. Efficacy and Safety of Aripiprazole in the Acute Treatment of Schizophrenia in Chinese Patients With Risperidone as an Active Control: A Randomized Trial. J Clin Psychiatry. 2007;68:29-36.

Park T, Kuntz KM. Cost-Effectiveness of Second-Generation Antipsychotics for the Treatment of Schizophrenia. Value Health. 2014;17:310-9.

Komossa K, Rummel-Kluge C, Schwarz S, Schmid F, Hunger H, Kissling W, et al. Risperidone versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2011(1).


  • There are currently no refbacks.